NCT02444546View on ClinicalTrials.gov

Wild-Type Reovirus in Combination With Sargramostim in Treating Younger Patients With High-Grade Relapsed or Refractory Brain Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

June 21, 2015

Primary Completion Date

July 13, 2018

Study Completion Date

November 21, 2022

Conditions
Childhood AstrocytomaChildhood Atypical Teratoid/Rhabdoid TumorDiffuse Intrinsic Pontine GliomaGliomaRecurrent Childhood Anaplastic OligodendrogliomaRecurrent Childhood Brain NeoplasmRecurrent Childhood GlioblastomaRecurrent Childhood MedulloblastomaRecurrent Primitive Neuroectodermal TumorRefractory Brain Neoplasm
Interventions
OTHER

Laboratory Biomarker Analysis

Correlative studies

BIOLOGICAL

Sargramostim

Given SC

BIOLOGICAL

Wild-type Reovirus

Given IV

Trial Locations (1)

55905

Mayo Clinic, Rochester

Sponsors

Lead Sponsor

Mayo Clinic
All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Mayo Clinic

OTHER